1261 related articles for article (PubMed ID: 33743846)
1. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
[TBL] [Abstract][Full Text] [Related]
3. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study.
Moore S; Hill EM; Tildesley MJ; Dyson L; Keeling MJ
Lancet Infect Dis; 2021 Jun; 21(6):793-802. PubMed ID: 33743847
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
[TBL] [Abstract][Full Text] [Related]
5. Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis.
Stevenson M; Metry A; Messenger M
Health Technol Assess; 2021 Jun; 25(39):1-74. PubMed ID: 34142943
[TBL] [Abstract][Full Text] [Related]
6. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
Whittles LK; Didelot X; White PJ
Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
[TBL] [Abstract][Full Text] [Related]
7. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
Lugnér AK; van Boven M; de Vries R; Postma MJ; Wallinga J
BMJ; 2012 Jul; 345():e4445. PubMed ID: 22791791
[TBL] [Abstract][Full Text] [Related]
9. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
10. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
[TBL] [Abstract][Full Text] [Related]
11. Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection.
Abbas K; Procter SR; van Zandvoort K; Clark A; Funk S; Mengistu T; Hogan D; Dansereau E; Jit M; Flasche S;
Lancet Glob Health; 2020 Oct; 8(10):e1264-e1272. PubMed ID: 32687792
[TBL] [Abstract][Full Text] [Related]
12. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
[TBL] [Abstract][Full Text] [Related]
13. Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.
Wang Y; Luangasanatip N; Pan-Ngum W; Isaranuwatchai W; Prawjaeng J; Saralamba S; Painter C; Briones JR; Teerawattananon Y
Eur J Health Econ; 2023 Jul; 24(5):735-748. PubMed ID: 35951243
[TBL] [Abstract][Full Text] [Related]
14. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
Kohli M; Maschio M; Becker D; Weinstein MC
Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: a modelling and economic analysis study.
Drakesmith M; Collins B; Jones A; Nnoaham K; Thomas DR
BMC Health Serv Res; 2022 Sep; 22(1):1190. PubMed ID: 36138455
[TBL] [Abstract][Full Text] [Related]
16. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study.
Jentsch PC; Anand M; Bauch CT
Lancet Infect Dis; 2021 Aug; 21(8):1097-1106. PubMed ID: 33811817
[TBL] [Abstract][Full Text] [Related]
17. Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region.
Liu Y; Sandmann FG; Barnard RC; Pearson CAB; ; Pastore R; Pebody R; Flasche S; Jit M
medRxiv; 2021 Jul; ():. PubMed ID: 34282421
[TBL] [Abstract][Full Text] [Related]
18. Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination.
Bartsch SM; Wedlock PT; O'Shea KJ; Cox SN; Strych U; Nuzzo JB; Ferguson MC; Bottazzi ME; Siegmund SS; Hotez PJ; Lee BY
J Infect Dis; 2021 Sep; 224(6):938-948. PubMed ID: 33954775
[TBL] [Abstract][Full Text] [Related]
19. Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US.
Flaxman AD; Issema R; Barnabas RV; Ross JM
JAMA Netw Open; 2022 Apr; 5(4):e228632. PubMed ID: 35452104
[TBL] [Abstract][Full Text] [Related]
20. Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis.
Stevenson M; Metry A; Messenger M
Health Technol Assess; 2021 Mar; 25(21):1-68. PubMed ID: 33764295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
